About: High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study
Creator	Hematol, Ann Verdonck, L Cornelissen, J Daenen, S Deenik, W Löwenberg, B Ossenkoppele, G Schattenberg, A Schouten, H Smit, W Van Der Holt, B Verhoef, G Westveer, P Wittebol, S Zachée, P
topic	covid:d9a5c2faf2fed55a9f69ffc63f5a6237d34d3a2a#this
Source	PMC
abstract	A prospective randomized phase III study was performed to evaluate whether intensified cytarabine would induce a higher response rate and longer event-free interval as compared to low-dose cytarabine in chronic myeloid leukemia (CML). One hundred and eighteen patients with CML in early chronic phase entered the study. Twenty-eight out of 32 patients assigned to group A received two cycles of a combination of intensified cytarabine and idarubicin followed by interferon alfa (IFN-α) maintenance, 28 patients in group B received standard treatment by a combination of low-dose cytarabine and IFN-α. Forty-nine patients with a human leukocyte antigen-identical sibling donor proceeded to allogeneic stem cell transplantation (allo-SCT) and nine patients were excluded from the analysis. Hematological response was observed in 97% of the patients in group A vs 86% of the patients in group B during the first year of treatment. In group A, 16 patients (50%) achieved a major cytogenetic response, which compared to seven patients (25%) with a major cytogenetic response in group B. With a median follow-up of 58 months (range 34–76), event-free survival was not significantly different between arms A and B. The estimated 5-year survival rate was 56% in the intensified arm and 77% in the low-dose arm (P = 0.05). Recipients of allo-SCT showed a 5-year estimated survival rate of 55%. Although intensified cytarabine induced a higher initial percentage of major and complete cytogenetic responses, responses were not sustained by IFN-α maintenance therapy.
has issue date	2006-10-10(xsd:dateTime)
bibo:doi	10.1007/s00277-006-0186-1
bibo:pmid	17031690
has license	no-cc
sha1sum (hex)	d9a5c2faf2fed55a9f69ffc63f5a6237d34d3a2a
schema:url	https://doi.org/10.1007/s00277-006-0186-1
resource representing a document's title	High-vs low-dose cytarabine combined with interferon alfa in patients with first chronic phase chronic myeloid leukemia. A prospective randomized phase III study
has PubMed Central identifier	PMC7101742
has PubMed identifier	17031690
schema:publication	Ann Hematol
resource representing a document's body	covid:d9a5c2faf2fed55a9f69ffc63f5a6237d34d3a2a#body_text
is http://vocab.deri.ie/void#inDataset of	proxy:http/ns.inria.fr/covid19/d9a5c2faf2fed55a9f69ffc63f5a6237d34d3a2a
is schema:about of	named entity 'cytarabine' named entity 'evaluate' named entity 'assigned' named entity 'patients' named entity 'intensified' named entity 'estimated' named entity 'RESPONSE' named entity 'CHRONIC MYELOID LEUKEMIA' named entity 'FORTY-NINE' named entity 'IDENTICAL' named entity 'ONE HUNDRED AND EIGHTEEN' named entity 'EVENT-FREE SURVIVAL' named entity 'TREATMENT' named entity 'SUSTAINED' named entity 'INITIAL' named entity 'patients' named entity 'The' named entity 'cytarabine' named entity 'interferon alfa' named entity 'group B' named entity 'cytarabine' named entity 'complete' named entity 'intensified' named entity 'sustained' named entity 'chronic myeloid leukemia' named entity 'IFN' named entity 'cytarabine' named entity 'cytarabine' named entity 'CML' named entity 'idarubicin' named entity 'standard treatment' named entity 'cytarabine' named entity 'estimated' named entity 'kinase' named entity 'log-rank test' named entity 'imatinib' named entity 'cytarabine' named entity 'cytarabine' named entity 'chemotherapy' named entity 'chemotherapy' named entity 'Ph chromosome' named entity 'Philadelphia' named entity 'follow-up' named entity 'cytarabine' named entity 'hydroxyurea' named entity 'allogeneic' named entity 'chronic phase' named entity 'cytogenetic' named entity 'MUD' named entity 'HLA' named entity 'IFN' named entity 'combination therapies' named entity 'cytarabine' named entity 'cytogenetic' named entity 'acquired resistance' named entity 'hydroxyurea' named entity 'dose response' named entity 'SCT' named entity 'IFN' named entity 'toxicity' named entity 'IFN' named entity 'cytarabine' named entity 'tyrosine kinase inhibitor' named entity 'gene amplification' named entity 'Ph chromosome'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software